Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
ZacksXenetic Biosciences (XBIO) delivered earnings and revenue surprises of 1.27% and 21.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?